Labriola et al analyzed tumor specimens of metastatic ccRCC treated with IO and found no correlation between therapy response and traditional efficacy markers such as TMB and PD‐L1 expression.12 This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.